Pseudomonas Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Pseudomonas stocks.

Pseudomonas Stocks Recent News

Date Stock Title
May 10 INSM Insmed First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
May 10 GLYC GlycoMimetics GAAP EPS of -$0.17 in-line
May 9 INSM Insmed, Inc. (INSM) Q1 2024 Earnings Call Transcript
May 9 GLYC GlycoMimetics, Inc. (GLYC) Corporate Update Call Transcript
May 9 INSM Insmed (INSM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
May 9 INSM Insmed (INSM) Reports Q1 Loss, Lags Revenue Estimates
May 9 INSM Insmed reports mixed Q1 results; reaffirms FY24 outlook
May 9 INSM Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update
May 8 INBX Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger
May 8 INSM Insmed Q1 2024 Earnings Preview
May 8 GLYC GlycoMimetics Q1 2024 Earnings Preview
May 8 INSM Should You Buy Insmed (INSM) Ahead of Earnings?
May 8 GLYC Uproleselan’s failed Phase III AML trial shakes up GlycoMimetics’ future
May 7 INSM Will Tango Therapeutics, Inc. (TNGX) Report Negative Q1 Earnings? What You Should Know
May 7 INSM Insmed To Present at the BofA Securities Health Care Conference 2024
May 7 INSM We Think Some Shareholders May Hesitate To Increase Insmed Incorporated's (NASDAQ:INSM) CEO Compensation
May 7 GLYC GlycoMimetics reports data from Phase III AML treatment trial
May 6 GLYC GlycoMimetics plummets 77% as phase 3 leukemia therapy uproleselan fails
May 6 GLYC GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Pseudomonas

Pseudomonas is a genus of Gram-negative, Gammaproteobacteria, belonging to the family Pseudomonadaceae and containing 191 validly described species. The members of the genus demonstrate a great deal of metabolic diversity and consequently are able to colonize a wide range of niches. Their ease of culture in vitro and availability of an increasing number of Pseudomonas strain genome sequences has made the genus an excellent focus for scientific research; the best studied species include P. aeruginosa in its role as an opportunistic human pathogen, the plant pathogen P. syringae, the soil bacterium P. putida, and the plant growth-promoting P. fluorescens.
Because of their widespread occurrence in water and plant seeds such as dicots, the pseudomonads were observed early in the history of microbiology. The generic name Pseudomonas created for these organisms was defined in rather vague terms by Walter Migula in 1894 and 1900 as a genus of Gram-negative, rod-shaped and polar-flagellated bacteria with some sporulating species, the latter statement was later proved incorrect and was due to refractive granules of reserve materials. Despite the vague description, the type species, Pseudomonas pyocyanea (basonym of Pseudomonas aeruginosa), proved the best descriptor.

Browse All Tags